Short description
Develop diagnostic tests that identify the unique properties of each patients’ cancer to inform on how best to manage their disease.
Description
QDx is a biotechnology company on a mission to make precision oncology the standard of care. We achieve this by developing accessible and scalable diagnostic tools that leverage the power of big data and machine learning. Our proprietary algorithms scour vast genomic databases to identify key biomarkers linked to patient survival outcomes. This translates into diagnostic tests that provide physicians with biologically informative data, enabling them to personalize cancer treatment plans (precision oncology). By avoiding unnecessary surgeries, and treatments, QDx not only improves patient outcomes but also reduces healthcare costs. Our cloud-based platform facilitates global deployment of these tests in an asset-light manner, along with our central marketplace that streamlines test selection, ordering, and data exchange for all stakeholders. The central marketplace is a licensable SaaS solution to power the widespread adoption of precision oncology tests, seamlessly connection patients to the ever-evolving world of molecular diagnostics. Ultimately, QDx empowers physicians, patients, and other test developers with actionable insights, leading to a more effective and efficient approach to cancer care.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Calgary, Alberta, Canada, North America
Founded on
June 2, 2017
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Blurry Noaccess, Noway Youcantaccess
Sign in for full access
Founders
Brandon Friedt, Cynthia Stretch, Farshad Farshidfar, Oliver Bathe